Stonepine Capital Management LLC Increases Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Stonepine Capital Management LLC increased its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 14.5% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 189,308 shares of the biotechnology company’s stock after buying an additional 23,911 shares during the quarter. Anika Therapeutics comprises approximately 3.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 9th biggest position. Stonepine Capital Management LLC owned about 1.29% of Anika Therapeutics worth $4,676,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Riverwater Partners LLC grew its stake in shares of Anika Therapeutics by 539.1% in the third quarter. Riverwater Partners LLC now owns 101,996 shares of the biotechnology company’s stock worth $2,552,000 after acquiring an additional 86,037 shares during the period. Meros Investment Management LP grew its position in Anika Therapeutics by 25.0% in the 2nd quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock worth $5,388,000 after purchasing an additional 42,587 shares during the period. Renaissance Technologies LLC raised its stake in Anika Therapeutics by 6.9% during the 2nd quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after buying an additional 38,412 shares during the last quarter. Boston Partners bought a new position in shares of Anika Therapeutics during the 1st quarter valued at $733,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Anika Therapeutics by 5.1% in the 2nd quarter. Acadian Asset Management LLC now owns 442,944 shares of the biotechnology company’s stock worth $11,217,000 after buying an additional 21,517 shares during the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Trading Up 0.3 %

Shares of NASDAQ:ANIK traded up $0.06 during midday trading on Wednesday, hitting $17.78. The company had a trading volume of 2,623 shares, compared to its average volume of 70,846. The company has a fifty day moving average of $21.92 and a two-hundred day moving average of $24.52. Anika Therapeutics, Inc. has a 12-month low of $16.00 and a 12-month high of $29.11.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ANIK shares. StockNews.com cut Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Barrington Research reduced their price target on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.